Virios Therapeutics, Inc. (VIRI) Q2 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Angela Walsh, Senior Vice President of Finance and Treasurer of Vireos Therapeutics. Please proceed, Angela. Thank you. Good morning, everyone, and thank you for joining us on today's conference call. We are pleased to be with you today to discuss Vireos Therapeutics second quarter financial results and corporate update. Please note that our financial results press release is now available on our website. Before we begin, I'd like to remind everyone that statements made during this conference call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involved risks and insurgencies that can cause actual results to differ materially from the information expressed or implied by these forward-looking statements. For more information regarding such risks and insurgencies, please see the risk factors outlined in the company's filings with the SEC. Any forward-looking statements are made only as of today, and we disclaim any obligation to update these forward-looking statements other than as required by law. Please see the forward-looking statements section in our financial results release issued this morning for more information. It is now my pleasure to turn the call over to our CEO, Greg Duncan. Thank you, Angela, and good morning to all of you joining us on today's quarter two 2023 earnings update. We have three specific topics to cover on today's call. First, I will begin with an update on our submission to the Food and Drug Administration, or FDA as you know it, to progress our lead development candidate, IMC1, into phase three development as a possible treatment for the millions of patients who suffer from the consequences of fibromyalgia. Second, we are very pleased to have our chief medical office...